Does the media favor GMAB or ORKA?

In the previous week, Genmab A/S had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Genmab A/S and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Genmab A/S's score of 1.03 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORKA or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Ascendis Pharma A/S's score of 1.27 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORKA or BBIO?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 5 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 1.50 beat Oruka Therapeutics' score of 1.45 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ORKA or ELAN?

In the previous week, Elanco Animal Health had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Elanco Animal Health's score of 1.27 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORKA or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Axsome Therapeutics' score of 1.03 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oruka Therapeutics (ORKA) Competitors

$92.16 +0.21 (+0.23%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$91.68 -0.48 (-0.52%)

As of 07/24/2026 07:34 PM Eastern

Compare

ORKA vs. GMAB, ASND, BBIO, ELAN, and AXSM

Should you buy Oruka Therapeutics stock or one of its competitors? MarketBeat compares Oruka Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oruka Therapeutics include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Oruka Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Genmab A/S has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.90B	4.61	$963M	$1.32	21.87
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Genmab A/S has a net margin of 21.05% compared to Oruka Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Oruka Therapeutics	N/A	-26.16%	-25.00%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Genmab A/S had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Genmab A/S and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Genmab A/S's score of 1.03 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

Genmab A/S currently has a consensus price target of $39.28, indicating a potential upside of 36.05%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 45.72%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Genmab A/S beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Oruka Therapeutics (NASDAQ:ORKA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Oruka Therapeutics presently has a consensus target price of $134.30, indicating a potential upside of 45.72%. Ascendis Pharma A/S has a consensus target price of $296.72, indicating a potential upside of 16.88%. Given Oruka Therapeutics' higher probable upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oruka Therapeutics has a beta of -0.35, indicating that its share price is 135% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Oruka Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Oruka Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Ascendis Pharma A/S	$814.57M	19.44	-$258M	$8.67	29.28

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Ascendis Pharma A/S's score of 1.27 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Oruka Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to BridgeBio Pharma?

Oruka Therapeutics (NASDAQ:ORKA) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, BridgeBio Pharma had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 5 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 1.50 beat Oruka Therapeutics' score of 1.45 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oruka Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
BridgeBio Pharma	$579.96M	28.37	-$724.93M	-$3.74	N/A

Oruka Therapeutics has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Oruka Therapeutics currently has a consensus target price of $134.30, suggesting a potential upside of 45.72%. BridgeBio Pharma has a consensus target price of $95.21, suggesting a potential upside of 13.32%. Given Oruka Therapeutics' higher possible upside, equities analysts plainly believe Oruka Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Oruka Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

BridgeBio Pharma beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Elanco Animal Health?

Oruka Therapeutics (NASDAQ:ORKA) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Oruka Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Elanco Animal Health	-4.95%	7.42%	3.66%

In the previous week, Elanco Animal Health had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Elanco Animal Health's score of 1.27 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Elanco Animal Health	$4.89B	2.54	-$232M	-$0.50	N/A

Oruka Therapeutics presently has a consensus price target of $134.30, suggesting a potential upside of 45.72%. Elanco Animal Health has a consensus price target of $28.73, suggesting a potential upside of 15.37%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oruka Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Oruka Therapeutics and Elanco Animal Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Axsome Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Oruka Therapeutics' return on equity of -26.16% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Oruka Therapeutics currently has a consensus target price of $134.30, suggesting a potential upside of 45.72%. Axsome Therapeutics has a consensus target price of $261.48, suggesting a potential upside of 8.50%. Given Oruka Therapeutics' higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Axsome Therapeutics had 8 more articles in the media than Oruka Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 5 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.45 beat Axsome Therapeutics' score of 1.03 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Axsome Therapeutics	$638.50M	19.42	-$183.17M	-$3.73	N/A

Summary

Oruka Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.55B	$3.08B	$6.88B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-47.50	20.29	27.00	23.71
Price / Sales	N/A	353.88	492.77	76.09
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	9.51	4.13	10.28	6.07
Net Income	-$105.43M	$65.94M	$3.60B	$331.84M
7 Day Performance	-0.58%	-4.18%	-1.25%	-1.53%
1 Month Performance	6.38%	-3.76%	-0.35%	-2.46%
1 Year Performance	546.74%	9.93%	18.41%	13.66%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	3.6307 of 5 stars	$92.16 +0.2%	$134.30 +45.7%	+547.6%	$5.55B	N/A	N/A	N/A	News Coverage Positive News
GMAB Genmab A/S	4.793 of 5 stars	$28.72 -0.9%	$38.21 +33.1%	+22.2%	$18.07B	$3.72B	21.76	3,029	Analyst Upgrade
ASND Ascendis Pharma A/S	4.7289 of 5 stars	$261.00 +0.5%	$295.67 +13.3%	+50.8%	$16.21B	$865.78M	30.10	1,189	Positive News Analyst Forecast
BBIO BridgeBio Pharma	2.982 of 5 stars	$81.38 +1.3%	$95.21 +17.0%	+84.0%	$15.73B	$502.08M	N/A	400	Positive News
ELAN Elanco Animal Health	3.7809 of 5 stars	$25.84 -0.4%	$28.55 +10.5%	+69.5%	$12.96B	$4.72B	N/A	9,400	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Oruka Therapeutics compare to Genmab A/S?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. GMAB, ASND, BBIO, ELAN, and AXSM

How does Oruka Therapeutics compare to Genmab A/S?

Which has better valuation & earnings, GMAB or ORKA?

Is GMAB or ORKA more profitable?

Do institutionals & insiders believe in GMAB or ORKA?

Does the media favor GMAB or ORKA?

Which has more risk & volatility, GMAB or ORKA?

Do analysts recommend GMAB or ORKA?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Do analysts rate ORKA or ASND?

Do institutionals & insiders hold more shares of ORKA or ASND?

Which has more volatility & risk, ORKA or ASND?

Is ORKA or ASND more profitable?

Which has stronger earnings & valuation, ORKA or ASND?

Does the media prefer ORKA or ASND?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Does the media refer more to ORKA or BBIO?

Do institutionals & insiders hold more shares of ORKA or BBIO?

Which has better valuation & earnings, ORKA or BBIO?

Which has more risk & volatility, ORKA or BBIO?

Do analysts rate ORKA or BBIO?

Is ORKA or BBIO more profitable?

Summary

How does Oruka Therapeutics compare to Elanco Animal Health?

Do insiders & institutionals hold more shares of ORKA or ELAN?

Which has more volatility & risk, ORKA or ELAN?

Is ORKA or ELAN more profitable?

Does the media refer more to ORKA or ELAN?

Which has higher valuation and earnings, ORKA or ELAN?

Do analysts rate ORKA or ELAN?

Summary

How does Oruka Therapeutics compare to Axsome Therapeutics?

Which has more volatility and risk, ORKA or AXSM?

Do insiders and institutionals hold more shares of ORKA or AXSM?

Is ORKA or AXSM more profitable?

Do analysts rate ORKA or AXSM?

Does the media refer more to ORKA or AXSM?

Which has preferable earnings & valuation, ORKA or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools